AcquiredStartups
Home/North America/Healthtech & bio
Acquisition · Healthtech & bio · United States

Johnson & Johnson to buy eye-drug startup Ollin Biosciences for $2.2 billion upfront

Founded in 2023, Ollin could fetch up to about $3.3 billion with milestones, while Blackstone has agreed to pay $750 million toward the Phase 3 trials of its lead drug.

ASAcquired deals deskNorth America16 November 2026 · 3 min read
Johnson & Johnson acquires Ollin Biosciences
Photo: Quintin Soloviev / Wikimedia Commons, CC BY 4.0

Johnson & Johnson said on November 16, 2026 that it has signed a definitive agreement to acquire Ollin Biosciences, a clinical-stage company developing treatments for serious eye diseases, for $2.2 billion upfront. Ollin's shareholders could receive up to approximately $1.125 billion more in regulatory and commercial milestone payments, bringing the potential total to about $3.3 billion.

The deal is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. J&J did not say how the upfront payment will be split between cash and other consideration, and said it would explain the accounting treatment on or before closing.

Alongside the purchase, J&J agreed a separate development funding deal with Blackstone Life Sciences that takes effect only if the acquisition closes. Blackstone will pay J&J a total of $750 million over several years to fully fund Phase 3 development of Ollin's lead drug, OLN324, and in return can receive certain regulatory and sales milestone payments and single-digit royalties.

What Ollin built

OLN324 is an experimental bispecific antibody that blocks two pathways involved in retinal disease, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). J&J describes it as a next-generation molecule with high potency against Ang2 and a small protein format, known as a minibody, that could give better control of fluid in the retina. It is being developed for wet age-related macular degeneration and diabetic macular edema, which J&J says together affect more than 40 million people worldwide.

Ollin completed a 164-patient randomised study called JADE that compared OLN324 head to head with faricimab in patients with both conditions. According to Ollin, OLN324 produced faster and greater improvements in retinal anatomy than faricimab in both conditions, along with numerically greater gains in vision. The company has held an End-of-Phase 2 meeting with the US Food and Drug Administration and received scientific advice from the European Medicines Agency, and planned to start global Phase 3 trials in the second half of 2026.

Ollin also has a second programme, OLN102, a bispecific antibody aimed at thyroid eye disease and Graves' disease that was discovered by and is being developed with VelaVigo.

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control.”Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson
Funding historyTotal raised $430m
2026Series BTCGX and ARCH Venture Partners$330m

Why J&J is buying

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, vice president and ophthalmology disease area leader at J&J. He said the data so far point to a clinical profile that could reduce retinal fluid more effectively and allow longer gaps between treatments.

J&J said the deal would strengthen its position in ophthalmology. Dealroom described retinal medicines as a gap in J&J's portfolio and noted that the company has recently agreed other large drug deals, including Firefly Bio for $1 billion and Intra-Cellular Therapies for $14.6 billion.

The Financial Times first reported that the two companies were in talks before the agreement was announced, according to Dealroom. More than a third of the headline value depends on future clinical and commercial milestones.

The founders and the funding

Ollin was founded in 2023 and is based in Austin, Texas. Its co-founder and chief executive is Jason Ehrlich, a physician-scientist. The company came out of stealth in 2025 with $100 million in funding, according to Dealroom, with ARCH Venture Partners as a founding investor.

In June 2026 Ollin raised an oversubscribed $330 million Series B co-led by TCGX and ARCH Venture Partners, according to Pulse 2.0. Other participants included a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board, RA Capital Management, accounts advised by T. Rowe Price, an unnamed sovereign wealth fund, Mubadala Capital and Monograph Capital. That brought total funding to about $430 million.

At the time of the Series B, Ehrlich said the founders started Ollin to challenge the status quo in ophthalmology and pointed to a $15 billion market for retinal drugs.

A busy market for biotech deals

The purchase lands during a strong stretch for drug-industry M&A. Dealroom cited BioWorld data showing biopharma deal-making reached an eight-year high in October 2026.

For Ollin's investors the exit comes roughly a year after the company launched and five months after its Series B. Because Blackstone will fund Phase 3, J&J will carry less of the trial cost itself, though it will owe Blackstone milestone payments and royalties if OLN324 reaches the market.

Sources